Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

In by alicia.green

Locations
Jacksonville - Florida Eye Specialist (Gate)
Condition
Eye Disease, Ocular Hypertension, Open-Angle Glaucoma

Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

  • Hidden
  • This field is for validation purposes and should be left unchanged.

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

clinicaltrials.gov

Eligibility

Inclusion Criteria
  1. Diagnosis of open-angle glaucoma or ocular hypertension in both eyes
  2. Qualifying IOP at 3 time points through the day at 2 visits following washout of IOP-lowering medication, if applicable
  3. Qualifying best-corrected visual acuity in each eye
  4. Ability to provide informed consent and follow study instructions
Exclusion Criteria
  1. Narrow anterior chamber angles or disqualifying corneal thickness in either eye
  2. Clinically significant ocular disease in either eye
  3. Previous complicated surgery or certain types of glaucoma surgery in either eye
  4. Incisional ocular surgery or severe trauma in either eye within the past 6 months
  5. Uncontrolled systemic disease
Back to Current Studies